Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

Immunocore, a UK-based bispecific immunotherapy developer backed by pharmaceutical firms Eli Lilly and WuXi AppTec, has floated on the Nasdaq Global Select Market having raised over $258m in its initial public offering. The offering consisted of approximately 9.94 million American Depositary Shares priced at $26.00 each, above the offering’s $23 to $25 range. Immunocore concurrently…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.